- CUE Dashboard
- Financials
- Filings
-
Holdings
- Transcripts
- ETFs
- Insider
- Institutional
- Shorts
-
CORRESP Filing
Cue Biopharma (CUE) CORRESPCorrespondence with SEC
Filed: 17 Jul 18, 12:00am
Cue Biopharma, Inc.
675 W. Kendall Street
Cambridge, MA 02142
July 17, 2018
VIA EDGAR
Securities and Exchange Commission
100 F Street, N.E.
Washington, D.C. 20549
Attention: Abigail Jacobs
Re: | Cue Biopharma, Inc. |
Registration Statement on FormS-1 |
FileNo. 333-225800 |
Ladies and Gentlemen:
Pursuant to Rule 461 promulgated under the Securities Act of 1933, as amended, registrant Cue Biopharma, Inc. (the “Company”) hereby respectfully requests that the above-referenced Registration Statement on FormS-1 (the “Registration Statement”) be declared effective at 4:00 p.m., Eastern Time, on Thursday, July 19, 2018, or as soon thereafter as is practicable.
Please direct any questions regarding this request to Mark R. Busch ((704)331-7440; mark.busch@klgates.com) of K&L Gates LLP. In addition, please notify Mr. Busch when this request for acceleration has been granted.
Sincerely,
/s/ Daniel R. Passeri
Daniel R. Passeri
Chief Executive Officer